Analyst for Corinne's questions to Amylyx Pharmaceuticals Inc (AMLX) leadership • Q3 2024
Question
An analyst speaking on behalf of Corinne asked about the addressable market size for post-bariatric hypoglycemia (PBH) patients who are effectively managed by current therapies, and inquired about the gating factors for initiating the Phase III PBH study.
Answer
James Frates, Chief Financial Officer, estimated the market at approximately 160,000 people with persistent PBH, derived from the 8% of bariatric surgery patients who are not managed by available therapies. Dr. Camille Bedrosian, Chief Medical Officer, added that the company is on track to initiate the trial in Q1 2025, noting strong enthusiasm from clinical sites.